Search

Your search keyword '"Kusunoki, Susumu"' showing total 1,156 results
Start Over Author "Kusunoki, Susumu"
1,156 results on '"Kusunoki, Susumu"'

1. Takotsubo cardiomyopathy in Guillain–Barré syndrome

Author

Terayama, Atsushi, Kuwahara, Motoi, Yoshikawa, Keisuke, Yamagishi, Yuko, Samukawa, Makoto, Yamashita, Shoko, Onishi, Kyohei, Nagano, Tomoya, Tatsumi, Chikao, Ishii, Junko, Kawamoto, Michi, Tokashiki, Takashi, Deguchi, Shoko, Deguchi, Kentaro, Ishida, Atsushi, Baba, Yasuhiko, Yamaguchi, Shigeki, Kusunoki, Susumu, and Nagai, Yoshitaka

Published
2024
Full Text
View/download PDF

10. Diagnostic testing and treatment in Japanese patients with a diagnosis code for chronic inflammatory demyelinating polyradiculoneuropathy: A claims database analysis.

Author

Kuwahara, Motoi, Kusunoki, Susumu, Igarashi, Ataru, Akiyama, Satoshi, Fukushima, Taku, and Doi, Mamoru

Subjects
*CHRONIC inflammatory demyelinating polyradiculoneuropathy, *MEDICAL databases, *NERVE conduction studies, *SYSTEMIC lupus erythematosus, *MAGNETIC resonance imaging
Abstract

Objectives Methods Results Conclusion Reports of real‐world data concerning chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) are limited in Japan. This study aimed to investigate the diagnostic testing and treatment performed in patients diagnosed with CIDP in Japan.Using a Japanese commercial medical information database, we analyzed diagnostic tests, differential diseases, and treatments for patients with a diagnosis code for CIDP between April 13, 2008 and August 31, 2018.Of the 4564 patients with a diagnosis code for CIDP, 1658 patients were confirmed as newly assigned with the diagnosis code during the study period. Diagnostic tests performed before assignment of the diagnosis code for CIDP included nerve conduction studies in 48.1%, magnetic resonance imaging in 40.5%, and cerebrospinal fluid tests in 38.4%. Other diseases with codes that were assigned at the time of the CIDP diagnosis included Guillain–Barré syndrome in 8.1%, Sjögren syndrome in 4.4%, and systemic lupus erythematosus in 3.7%. Initial treatments performed after the assignment of the new diagnosis code for CIDP were intravenous immunoglobulin (IVIg) in 54.3%, corticosteroids (CS) in 45.4%, and plasmapheresis in 2.3%. The event‐free survival rates for predefined specific safety‐related events at 1000 d were 90.0% for any event in patients receiving IVIg monotherapy and 71.7% for any event in patients receiving CS monotherapy.Diagnostic testing and treatment performed in clinical practice was shown through the analysis of real‐world data of Japanese patients with a diagnosis code for CIDP. These findings might contribute to developments in clinical practice for Japanese CIDP patients. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

11. Efficacy and safety of eculizumab in Guillain‐Barré syndrome: A phase 3, multicenter, double‐blind, randomized, placebo‐controlled clinical trial.

Author

Kuwabara, Satoshi, Kusunoki, Susumu, Kuwahara, Motoi, Yamano, Yoshihisa, Nishida, Yoichiro, Ishida, Hirokazu, Kasuya, Tomoyuki, Kupperman, Erik, Lin, Qun, Frick, Glen, and Misawa, Sonoko

Subjects
*INTRAVENOUS immunoglobulins, *PLACEBOS, *IMMUNOSUPPRESSIVE agents, *MEDICAL quality control, *PATIENT safety, *RESEARCH funding, *STATISTICAL sampling, *BLIND experiment, *GUILLAIN-Barre syndrome, *TREATMENT effectiveness, *RANDOMIZED controlled trials, *DESCRIPTIVE statistics, *MONOCLONAL antibodies, *INTRAVENOUS therapy, *ODDS ratio, *RESEARCH, *CONVALESCENCE, *COMPARATIVE studies, *CONFIDENCE intervals, *PLASMA exchange (Therapeutics), *PHARMACODYNAMICS
Abstract

Background and Aims: Guillain‐Barré syndrome (GBS) is an acute, self‐limited, immune‐mediated peripheral neuropathy. Current treatments for GBS include intravenous immunoglobulin (IVIg) and plasma exchange, which may not sufficiently benefit severely affected patients. This study evaluated the efficacy and safety of eculizumab add‐on therapy to IVIg (standard‐of‐care treatment) in patients with severe GBS. Methods: This phase 3, multicenter, double‐blind, randomized, placebo‐controlled clinical trial (NCT04752566), enrolled Japanese adults (age ≥ 18 years) with severe GBS (Hughes functional grade [FG] score FG3 or FG4/FG5 within 2 weeks of onset of GBS). Participants were randomized 2:1 to receive intravenous infusion of eculizumab or placebo (once weekly for 4 weeks) with IVIg treatment with 20 weeks of follow‐up. Primary efficacy endpoint was the time to first reach FG score ≤1 (able to run). Key secondary endpoints were proportion of participants achieving FG ≤1 at weeks 8 and 24 and FG improvement ≥3 at week 24. Pharmacodynamic analysis of serum free C5 concentration over time was performed. Safety was evaluated. Results: The analysis included 57 participants (eculizumab, n = 37; placebo, n = 20). Primary endpoint was not achieved (hazard ratio, 0.9; 95% CI, 0.45–1.97; p =.89). Key secondary endpoints did not reach statistical significance. Serum C5 concentration was reduced by 99.99% at 1 h postdose and sustained to week 5 but returned to baseline at the end of follow‐up period. No new safety signals for eculizumab were identified. Interpretation: Although well tolerated, eculizumab treatment did not show significant effects on motor function recovery compared to placebo in patients with GBS. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

16. Electrodiagnostic subtyping in Guillain–Barré syndrome patients in the International Guillain–Barré Outcome Study

Author

Arends, Samuel, Drenthen, Judith, de Koning, Laura, van den Bergh, Peter, Hadden, Robert D. M., Kuwabara, Satoshi, Reisin, Ricardo C., Shahrizaila, Nortina, Ajroud‐Driss, Senda, Antonini, Giovanni, Attarian, Shahram, Balducci, Claudia, Bertorini, Tulio, Brannagan, Thomas H., Cavaletti, Guido, Chao, Chi‐Chao, Chavada, Govind, Dillmann, Klaus‐Ulrich, Dimachkie, Mazen M., Galassi, Giuliana, Gutiérrez‐Gutiérrez, Gerardo, Harbo, Thomas, Islam, Badrul, Islam, Zhahirul, Katzberg, Hans, Kusunoki, Susumu, Manganelli, Fiore, Miller, James A. L., Pardo, Julio, Pereon, Yann, Rajabally, Yusuf A., Sindrup, Soren, Stettner, Mark, Uncini, Antonino, Verhamme, Camiel, Vytopil, Michal, Waheed, Waqar, Jacobs, Bart C., Cornblath, David R., Arends, Samuel, Drenthen, Judith, de Koning, Laura, van den Bergh, Peter, Hadden, Robert D. M., Kuwabara, Satoshi, Reisin, Ricardo C., Shahrizaila, Nortina, Ajroud‐Driss, Senda, Antonini, Giovanni, Attarian, Shahram, Balducci, Claudia, Bertorini, Tulio, Brannagan, Thomas H., Cavaletti, Guido, Chao, Chi‐Chao, Chavada, Govind, Dillmann, Klaus‐Ulrich, Dimachkie, Mazen M., Galassi, Giuliana, Gutiérrez‐Gutiérrez, Gerardo, Harbo, Thomas, Islam, Badrul, Islam, Zhahirul, Katzberg, Hans, Kusunoki, Susumu, Manganelli, Fiore, Miller, James A. L., Pardo, Julio, Pereon, Yann, Rajabally, Yusuf A., Sindrup, Soren, Stettner, Mark, Uncini, Antonino, Verhamme, Camiel, Vytopil, Michal, Waheed, Waqar, Jacobs, Bart C., and Cornblath, David R.

Abstract

Background and purpose: Various electrodiagnostic criteria have been developed in Guillain–Barré syndrome (GBS). Their performance in a broad representation of GBS patients has not been evaluated. Motor conduction data from the International GBS Outcome Study (IGOS) cohort were used to compare two widely used criterion sets and relate these to diagnostic amyotrophic lateral sclerosis criteria. Methods: From the first 1500 patients in IGOS, nerve conduction studies from 1137 (75.8%) were available for the current study. These patients were classified according to nerve conduction studies criteria proposed by Hadden and Rajabally. Results: Of the 1137 studies, 68.3% (N = 777) were classified identically according to criteria by Hadden and Rajabally: 111 (9.8%) axonal, 366 (32.2%) demyelinating, 195 (17.2%) equivocal, 35 (3.1%) inexcitable and 70 (6.2%) normal. Thus, 360 studies (31.7%) were classified differently. The areas of differences were as follows: 155 studies (13.6%) classified as demyelinating by Hadden and axonal by Rajabally; 122 studies (10.7%) classified as demyelinating by Hadden and equivocal by Rajabally; and 75 studies (6.6%) classified as equivocal by Hadden and axonal by Rajabally. Due to more strictly defined cutoffs fewer patients fulfilled demyelinating criteria by Rajabally than by Hadden, making more patients eligible for axonal or equivocal classification by Rajabally. In 234 (68.6%) axonal studies by Rajabally the revised El Escorial (amyotrophic lateral sclerosis) criteria were fulfilled; in axonal cases by Hadden this was 1.8%. Conclusions and discussion: This study shows that electrodiagnosis in GBS is dependent on the criterion set utilized, both of which are based on expert opinion. Reappraisal of electrodiagnostic subtyping in GBS is warranted.

Published
2024

17. Predicting Outcome in Guillain-Barré Syndrome: International Validation of the Modified Erasmus GBS Outcome Score

Author

Doets, Alex Y, Lingsma, Hester F, Walgaard, Christa, Islam, Badrul, Papri, Nowshin, Davidson, Amy, Yamagishi, Yuko, Kusunoki, Susumu, Dimachkie, Mazen M, Waheed, Waqar, Kolb, Noah, Islam, Zhahirul, Mohammad, Quazi Deen, Harbo, Thomas, Sindrup, Soren H, Chavada, Govindsinh, Willison, Hugh J, Casasnovas, Carlos, Bateman, Kathleen, Miller, James AL, van den Berg, Bianca, Verboon, Christine, Roodbol, Joyce, Leonhard, Sonja E, Benedetti, Luana, Kuwabara, Satoshi, Van den Bergh, Peter, Monges, Soledad, Marfia, Girolama A, Shahrizaila, Nortina, Galassi, Giuliana, Péréon, Yann, Bürmann, Jan, Kuitwaard, Krista, Kleyweg, Ruud P, Marchesoni, Cintia, Sedano Tous, María J, Querol, Luis, Illa, Isabel, Wang, Yuzhong, Nobile-Orazio, Eduardo, Rinaldi, Simon, Schenone, Angelo, Pardo, Julio, Vermeij, Frederique H, Lehmann, Helmar C, Granit, Volkan, Cavaletti, Guido, Gutiérrez-Gutiérrez, Gerardo, Barroso, Fabio A, Visser, Leo H, Katzberg, Hans D, Dardiotis, Efthimios, Attarian, Shahram, van der Kooi, Anneke J, Eftimov, Filip, Wirtz, Paul W, Samijn, Johnny PA, Gilhuis, H Jacobus, Hadden, Robert DM, Holt, James KL, Sheikh, Kazim A, Karafiath, Summer, Vytopil, Michal, Antonini, Giovanni, Feasby, Thomas E, Faber, Catharina G, Gijsbers, Cees J, Busby, Mark, Roberts, Rhys C, Silvestri, Nicholas J, Fazio, Raffaella, van Dijk, Gert W, Garssen, Marcel PJ, Straathof, Chiara SM, Gorson, Kenneth C, and Jacobs, Bart C

Published
2021
Full Text
View/download PDF

18. Genome-wide association analysis identifies PLA2G4C as a susceptibility locus for Multiple System Atrophy

Author

Tsuji, Shoji, primary, Nakahara, Yasuo, additional, Mitsui, Jun, additional, Date, Hidetoshi, additional, Porto, Kristine Joyce, additional, Hyashi, Yasuhiro, additional, Yamashita, Atsushi, additional, Kusakabe, Yoshio, additional, Matsukawa, Takashi, additional, Ishiura, Hiroyuki, additional, Yasuda, Tsutomu, additional, Iwata, Atsushi, additional, Goto, Jun, additional, Ichikawa, Yaeko, additional, Momose, Yoshio, additional, Takahashi, Yuji, additional, Toda, Tatsushi, additional, Ohta, Rikifumi, additional, Yoshimura, Jun, additional, Morishita, Shinichi, additional, Gustavsson, Emil, additional, Christy, Darren, additional, Maczis, Melisa, additional, Kim, Han-Joon, additional, Park, Sung-Sup, additional, Zhang, Jin, additional, Gu, Weihong, additional, Scholz, Sonja, additional, Chelban, Viorica, additional, Mok, Kin, additional, Houlden, Henry, additional, Yabe, Ichiro, additional, Sasaki, Hidenao, additional, Matsushima, Masaaki, additional, Takashima, Hiroshi, additional, Kikuchi, Akio, additional, Aoki, Masashi, additional, Hara, Kenju, additional, Kakita, Akiyoshi, additional, Yamada, Mitsunori, additional, Takahashi, Hitoshi, additional, Onodera, Osamu, additional, Nishizawa, Masatoyo, additional, Watanabe, Hirohisa, additional, Ito, Mizuki, additional, Sobue, Gen, additional, Ishikawa, Kinya, additional, Mizusawa, Hidehiro, additional, Kanai, Kazuaki, additional, Kuwabara, Satoshi, additional, Arai, Kimihito, additional, Koyano, Shigeru, additional, Kuroiwa, Yoshiyuki, additional, Hasegawa, Kazuko, additional, Yuasa, Tatsuhiko, additional, Yasui, Kenichi, additional, Nakashima, Kenji, additional, Ito, Hijiri, additional, Izumi, Yuishin, additional, Kaji, Ryuji, additional, kato, Takeo, additional, Kusunoki, Susumu, additional, Osaki, Yasushi, additional, Horiuchi, Masahiro, additional, Yamamoto, Ken, additional, Shimada, Mihoko, additional, Miyagawa, Taku, additional, Kawai, Yosuke, additional, Nishida, Nao, additional, Tokunaga, Katsushi, additional, Durr, Alexandra, additional, Brice, Alexis, additional, Filla, Alessandro, additional, Klockgether, Thomas, additional, Wuellner, Ullrich, additional, Tanner, Caroline, additional, Kukull, Walter, additional, Lee, Virginia, additional, Masliah, Eliezer, additional, Low, Phillip, additional, Sandroni, Paola, additional, Ozelius, Laurie, additional, Foroud, Tatiana, additional, Farrer, Matthew, additional, and Trojanowski, John, additional

Published
2024
Full Text
View/download PDF

19. Long-term Effects of IL-6 Receptor Blockade Therapy on Regulatory Lymphocytes and Neutrophils in Neuromyelitis Optica Spectrum Disorder

Author

Matsuoka, Takako, primary, Araki, Manabu, additional, Lin, Youwei, additional, Okamoto, Tomoko, additional, Gold, Ralf, additional, Chihara, Norio, additional, Sato, Wakiro, additional, Kimura, Atsuko, additional, Tachimori, Hisateru, additional, Miyamoto, Katsuichi, additional, Kusunoki, Susumu, additional, and Yamamura, Takashi, additional

Published
2024
Full Text
View/download PDF

20. HLA genotype-clinical phenotype correlations in multiple sclerosis and neuromyelitis optica spectrum disorders based on Japan MS/NMOSD Biobank data

Author

Watanabe, Mitsuru, Nakamura, Yuri, Sato, Shinya, Niino, Masaaki, Fukaura, Hikoaki, Tanaka, Masami, Ochi, Hirofumi, Kanda, Takashi, Takeshita, Yukio, Yokota, Takanori, Nishida, Yoichiro, Matsui, Makoto, Nagayama, Shigemi, Kusunoki, Susumu, Miyamoto, Katsuichi, Mizuno, Masanori, Kawachi, Izumi, Saji, Etsuji, Ohashi, Takashi, Shimohama, Shun, Hisahara, Shin, Nishiyama, Kazutoshi, Iizuka, Takahiro, Nakatsuji, Yuji, Okuno, Tatsusada, Ochi, Kazuhide, Suzumura, Akio, Yamamoto, Ken, Kawano, Yuji, Tsuji, Shoji, Hirata, Makoto, Sakate, Ryuichi, Kimura, Tomonori, Shimizu, Yuko, Nagaishi, Akiko, Okada, Kazumasa, Hayashi, Fumie, Sakoda, Ayako, Masaki, Katsuhisa, Shinoda, Koji, Isobe, Noriko, Matsushita, Takuya, and Kira, Jun-ichi

Published
2021
Full Text
View/download PDF

23. CSF Findings in Relation to Clinical Characteristics, Subtype, and Disease Course in Patients With Guillain-Barré Syndrome

Author

Al-Hakem, Helle, Doets, Alex Y, Stino, Amro Maher, Zivkovic, Sasha A, Andersen, Henning, Willison, Hugh J, Cornblath, David R, Gorson, Kenneth C, Islam, Zhahirul, Mohammad, Quazi Deen, Sindrup, Søren Hein, Kusunoki, Susumu, Davidson, Amy, Casasnovas, Carlos, Bateman, Kathleen, Miller, James A L, van den Berg, Bianca, Verboon, Christine, Roodbol, Joyce, Leonhard, Sonja E, Arends, Samuel, Luijten, Linda W G, Benedetti, Luana, Kuwabara, Satoshi, Van den Bergh, Peter, Monges, Soledad, Marfia, Girolama A, Shahrizaila, Nortina, Galassi, Giuliana, Pereon, Yann, Bürmann, Jan, Kuitwaard, Krista, Kleyweg, Ruud P, Marchesoni, Cintia, Sedano Tous, María J, Querol, Luis, Martín-Aguilar, Lorena, Wang, Yuzhong, Nobile-Orazio, Eduardo, Rinaldi, Simon, Schenone, Angelo, Pardo, Julio, Vermeij, Frederique H, Waheed, Waqar, Lehmann, Helmar C, Granit, Volkan, Stein, Beth, Samijn, Johnny P A, van Dijk, Gert W, Jacobs, Bart C, Neurology, Medical Microbiology & Infectious Diseases, Public Health, and Immunology

Subjects
Neurology (clinical)
Abstract

BACKGROUND AND OBJECTIVES: To investigate CSF findings in relation to clinical and electrodiagnostic subtypes, severity, and outcome of Guillain-Barré syndrome (GBS) based on 1,500 patients in the International GBS Outcome Study. METHODS: Albuminocytologic dissociation (ACD) was defined as an increased protein level (>0.45 g/L) in the absence of elevated white cell count (4 days 84%. High CSF protein levels were associated with a demyelinating subtype, proximal or global muscle weakness, and a reduced likelihood of being able to run at week 2 (odds ratio [OR] 0.42, 95% CI 0.25-0.70; p = 0.001) and week 4 (OR 0.44, 95% CI 0.27-0.72; p = 0.001). Patients with the Miller Fisher syndrome, distal predominant weakness, and normal or equivocal nerve conduction studies were more likely to have lower CSF protein levels. CSF cell count was

Published
2023

26. European Academy of Neurology/Peripheral Nerve Society Guideline on diagnosis and treatment of Guillain–Barré syndrome

Author

van Doorn, Pieter A., primary, Van den Bergh, Peter Y. K., additional, Hadden, Robert D. M., additional, Avau, Bert, additional, Vankrunkelsven, Patrik, additional, Attarian, Shahram, additional, Blomkwist‐Markens, Patricia H., additional, Cornblath, David R., additional, Goedee, H. Stephan, additional, Harbo, Thomas, additional, Jacobs, Bart C., additional, Kusunoki, Susumu, additional, Lehmann, Helmar C., additional, Lewis, Richard A., additional, Lunn, Michael P., additional, Nobile‐Orazio, Eduardo, additional, Querol, Luis, additional, Rajabally, Yusuf A., additional, Umapathi, Thirugnanam, additional, Topaloglu, Haluk A., additional, and Willison, Hugh J., additional

Published
2023
Full Text
View/download PDF

27. Clinical Features of Acute Flaccid Myelitis Temporally Associated With an Enterovirus D68 Outbreak : Results of a Nationwide Survey of Acute Flaccid Paralysis in Japan, August–December 2015

Author

Acute Flaccid Myelitis Collaborative Study Investigators, Chong, Pin Fee, Kira, Ryutaro, Mori, Harushi, Okumura, Akihisa, Torisu, Hiroyuki, Yasumoto, Sawa, Shimizu, Hiroyuki, Fujimoto, Tsuguto, Hanaoka, Nozomu, Kusunoki, Susumu, Takahashi, Toshiyuki, Oishi, Kazunori, and Tanaka-Taya, Keiko

Published
2018

28. Oral fingolimod for chronic inflammatory demyelinating polyradiculoneuropathy (FORCIDP Trial): a double-blind, multicentre, randomised controlled trial

Author

Day, Timothy, Spies, Judith, Roberts, Leslie, Van Damme, Philip, Van den Bergh, Peter YK, Maertens de Noordhout, Alain, Dionne, Annie, Larue, Sandrine, Massie, Rami, Melanson, Michel, Camu, William, De Seze, Jérôme, Le Masson, Gwendal, Pouget, Jean, Schmidt, Jens, Kimiskidis, Vasilios K, Chapman, Joab, Drory, Vivian E, Fazio, Raffaella, Gallia, Francesca, Kusunoki, Susumu, Mori, Masahiro, Iijima, Masahiro, Okamoto, Tomoko, Baba, Masayuki, Faber, Catharina G, van Schaik, Ivo N, Fryze, Waldemar, Motta, Ewa, Selmaj, Krzysztof, Casasnovas, Carlos, Sola, Antonio Guerrero, Illa, Isabel, Holt, James, Miller, James AL, Lunn, Michael P, Brannagan, Thomas H, III, Brown, Martin, Kelemen, John, Iyadurai, Stanley, Rezania, Kourosh, Sharma, Khema R, Tandan, Rup, Gudesblatt, Mark, Lawson, Victoria, Amato, Anthony A, Hughes, Richard, Dalakas, Marinos C, Merkies, Ingemar, Latov, Norman, Léger, Jean-Marc, Nobile-Orazio, Eduardo, Sobue, Gen, Genge, Angela, Cornblath, David, Merschhemke, Martin, Ervin, Carolyn Marie, Agoropoulou, Catherine, and Hartung, Hans-Peter

Published
2018
Full Text
View/download PDF

29. Safety and efficacy of eculizumab in Guillain-Barré syndrome: a multicentre, double-blind, randomised phase 2 trial

Author

Misawa, S, Kuwabara, S, Sato, Y, Yamaguchi, N, Nagashima, K, Katayama, K, Sekiguchi, Y, Iwai, Y, Amino, H, Suichi, T, Yokota, T, Nishida, Y, Kanouchi, T, Kohara, N, Kawamoto, M, Ishii, J, Kuwahara, M, Suzuki, H, Hirata, K, Kokubun, N, Masuda, R, Kaneko, J, Yabe, I, Sasaki, H, Kaida, K, Takazaki, H, Suzuki, N, Suzuki, S, Nodera, H, Matsui, N, Tsuji, S, Koike, H, Yamasaki, R, Kusunoki, S, Nagashima, T, Shimizu, T, Hirotani, M, Kadoya, M, Nakahara, J, Shimizu, J, Tanaka, M, Sobue, G, Katsuno, M, Yamaguchi, H, Ogata, H, Misawa, Sonoko, Kuwabara, Satoshi, Sato, Yasunori, Yamaguchi, Nobuko, Nagashima, Kengo, Katayama, Kanako, Sekiguchi, Yukari, Iwai, Yuta, Amino, Hiroshi, Suichi, Tomoki, Yokota, Takanori, Nishida, Yoichiro, Kanouchi, Tadashi, Kohara, Nobuo, Kawamoto, Michi, Ishii, Junko, Kuwahara, Motoi, Suzuki, Hidekazu, Hirata, Koichi, Kokubun, Norito, Masuda, Ray, Kaneko, Juntaro, Yabe, Ichiro, Sasaki, Hidenao, Kaida, Ken-ichi, Takazaki, Hiroshi, Suzuki, Norihiro, Suzuki, Shigeaki, Nodera, Hiroyuki, Matsui, Naoko, Tsuji, Shoji, Koike, Haruki, Yamasaki, Ryo, and Kusunoki, Susumu

Published
2018
Full Text
View/download PDF

30. Diagnosis and management of Guillain–Barré syndrome in ten steps

Author

Leonhard, Sonja E., Mandarakas, Melissa R., Gondim, Francisco A. A., Bateman, Kathleen, Ferreira, Maria L. B., Cornblath, David R., van Doorn, Pieter A., Dourado, Mario E., Hughes, Richard A. C., Islam, Badrul, Kusunoki, Susumu, Pardo, Carlos A., Reisin, Ricardo, Sejvar, James J., Shahrizaila, Nortina, Soares, Cristiane, Umapathi, Thirugnanam, Wang, Yuzhong, Yiu, Eppie M., Willison, Hugh J., and Jacobs, Bart C.

Published
2019
Full Text
View/download PDF

32. Anti-Glycolipid Antibody Examination in Five EAE Models and Theiler’s Virus Model of Multiple Sclerosis: Detection of Anti-GM1, GM3, GM4, and Sulfatide Antibodies in Relapsing-Remitting EAE

Author

Moriguchi, Kota, primary, Nakamura, Yumina, additional, Park, Ah-Mee, additional, Sato, Fumitaka, additional, Kuwahara, Motoi, additional, Khadka, Sundar, additional, Omura, Seiichi, additional, Ahmad, Ijaz, additional, Kusunoki, Susumu, additional, and Tsunoda, Ikuo, additional

Published
2023
Full Text
View/download PDF

33. European Academy of Neurology/Peripheral Nerve Society Guideline on diagnosis and treatment of Guillain–Barré syndrome.

Author

van Doorn, Pieter A., Van den Bergh, Peter Y. K., Hadden, Robert D. M., Avau, Bert, Vankrunkelsven, Patrik, Attarian, Shahram, Blomkwist‐Markens, Patricia H., Cornblath, David R., Goedee, H. Stephan, Harbo, Thomas, Jacobs, Bart C., Kusunoki, Susumu, Lehmann, Helmar C., Lewis, Richard A., Lunn, Michael P., Nobile‐Orazio, Eduardo, Querol, Luis, Rajabally, Yusuf A., Umapathi, Thirugnanam, and Topaloglu, Haluk A.

Subjects
CHRONIC inflammatory demyelinating polyradiculoneuropathy, PERIPHERAL nervous system, ANTIBODY titer, RESPIRATORY insufficiency
Abstract

Guillain–Barré syndrome (GBS) is an acute polyradiculoneuropathy. Symptoms may vary greatly in presentation and severity. Besides weakness and sensory disturbances, patients may have cranial nerve involvement, respiratory insufficiency, autonomic dysfunction and pain. To develop an evidence‐based guideline for the diagnosis and treatment of GBS, using Grading of Recommendations, Assessment, Development and Evaluation (GRADE) methodology a Task Force (TF) of the European Academy of Neurology (EAN) and the Peripheral Nerve Society (PNS) constructed 14 Population/Intervention/Comparison/Outcome questions (PICOs) covering diagnosis, treatment and prognosis of GBS, which guided the literature search. Data were extracted and summarised in GRADE Summaries of Findings (for treatment PICOs) or Evidence Tables (for diagnostic and prognostic PICOs). Statements were prepared according to GRADE Evidence‐to‐Decision (EtD) frameworks. For the six intervention PICOs, evidence‐based recommendations are made. For other PICOs, good practice points (GPPs) are formulated. For diagnosis, the principal GPPs are: GBS is more likely if there is a history of recent diarrhoea or respiratory infection; CSF examination is valuable, particularly when the diagnosis is less certain; electrodiagnostic testing is advised to support the diagnosis; testing for anti‐ganglioside antibodies is of limited clinical value in most patients with typical motor‐sensory GBS, but anti‐GQ1b antibody testing should be considered when Miller Fisher syndrome (MFS) is suspected; nodal–paranodal antibodies should be tested when autoimmune nodopathy is suspected; MRI or ultrasound imaging should be considered in atypical cases; and changing the diagnosis to acute‐onset chronic inflammatory demyelinating polyradiculoneuropathy (A‐CIDP) should be considered if progression continues after 8 weeks from onset, which occurs in around 5% of patients initially diagnosed with GBS. For treatment, the TF recommends intravenous immunoglobulin (IVIg) 0.4 g/kg for 5 days, in patients within 2 weeks (GPP also within 2–4 weeks) after onset of weakness if unable to walk unaided, or a course of plasma exchange (PE) 12–15 L in four to five exchanges over 1–2 weeks, in patients within 4 weeks after onset of weakness if unable to walk unaided. The TF recommends against a second IVIg course in GBS patients with a poor prognosis; recommends against using oral corticosteroids, and weakly recommends against using IV corticosteroids; does not recommend PE followed immediately by IVIg; weakly recommends gabapentinoids, tricyclic antidepressants or carbamazepine for treatment of pain; does not recommend a specific treatment for fatigue. To estimate the prognosis of individual patients, the TF advises using the modified Erasmus GBS outcome score (mEGOS) to assess outcome, and the modified Erasmus GBS Respiratory Insufficiency Score (mEGRIS) to assess the risk of requiring artificial ventilation. Based on the PICOs, available literature and additional discussions, we provide flow charts to assist making clinical decisions on diagnosis, treatment and the need for intensive care unit admission. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

39. Genome-wide association study identifies a new susceptibility locus inPLA2G4Cfor Multiple System Atrophy

Author

Nakahara, Yasuo, primary, Mitsui, Jun, additional, Date, Hidetoshi, additional, Porto, Kristine Joyce, additional, Hayashi, Yasuhiro, additional, Yamashita, Atsushi, additional, Kusakabe, Yoshio, additional, Matsukawa, Takashi, additional, Ishiura, Hiroyuki, additional, Yasuda, Tsutomu, additional, Iwata, Atsushi, additional, Goto, Jun, additional, Ichikawa, Yaeko, additional, Momose, Yoshio, additional, Takahashi, Yuji, additional, Toda, Tatsushi, additional, Ohta, Rikifumi, additional, Yoshimura, Jun, additional, Morishita, Shinichi, additional, Gustavsson, Emil K, additional, Christy, Darren, additional, Maczis, Melissa, additional, Farrer, Matthew J., additional, Kim, Han-Joon, additional, Park, Sung-Sup, additional, Jeon, Beomseok, additional, Zhang, Jin, additional, Gu, Weihong, additional, Scholz, Sonja W., additional, Singleton, Andrew B., additional, Houlden, Henry, additional, Yabe, Ichiro, additional, Sasaki, Hidenao, additional, Matsushima, Masaaki, additional, Takashima, Hiroshi, additional, Kikuchi, Akio, additional, Aoki, Masashi, additional, Hara, Kenju, additional, Kakita, Akiyoshi, additional, Yamada, Mitsunori, additional, Takahashi, Hitoshi, additional, Onodera, Osamu, additional, Nishizawa, Masatoyo, additional, Watanabe, Hirohisa, additional, Ito, Mizuki, additional, Sobue, Gen, additional, Ishikawa, Kinya, additional, Mizusawa, Hidehiro, additional, Kanai, Kazuaki, additional, Kuwabara, Satoshi, additional, Arai, Kimihito, additional, Koyano, Shigeru, additional, Kuroiwa, Yoshiyuki, additional, Hasegawa, Kazuko, additional, Yuasa, Tatsuhiko, additional, Yasui, Kenichi, additional, Nakashima, Kenji, additional, Ito, Hijiri, additional, Izumi, Yuishin, additional, Kaji, Ryuji, additional, Kato, Takeo, additional, Kusunoki, Susumu, additional, Osaki, Yasushi, additional, Horiuchi, Masahiro, additional, Yamamoto, Ken, additional, Shimada, Mihoko, additional, Miyagawa, Taku, additional, Kawai, Yosuke, additional, Nishida, Nao, additional, Tokunaga, Katsushi, additional, Dürr, Alexandra, additional, Brice, Alexis, additional, Filla, Alessandro, additional, Klockgether, Thomas, additional, Wüllner, Ullrich, additional, Tanner, Caroline M., additional, Kukull, Walter A., additional, Lee, Virginia M.-Y., additional, Masliah, Eliezer, additional, Low, Phillip A., additional, Sandroni, Paola, additional, Ozelius, Laurie, additional, Foroud, Tatiana, additional, and Tsuji, Shoji, additional

Published
2023
Full Text
View/download PDF

40. Cerebrospinal Fluid Findings in Relation to Clinical Characteristics, Subtype, and Disease Course in Patients With Guillain-Barré Syndrome

Author

Al-Hakem, Helle, primary, Doets, Alex Y, additional, Stino, Amro Maher, additional, Zivkovic, Sasha A., additional, Andersen, Henning, additional, Willison, Hugh J, additional, Cornblath, David R, additional, Gorson, Kenneth C, additional, Islam, Zhahirul, additional, Mohammad, Quazi Deen, additional, Sindrup, Søren Hein, additional, Kusunoki, Susumu, additional, Davidson, Amy, additional, Casasnovas, Carlos, additional, Bateman, Kathleen, additional, Miller, James AL, additional, van den Berg, Bianca, additional, Verboon, Christine, additional, Roodbol, Joyce, additional, Leonhard, Sonja E, additional, Arends, Samuel, additional, Luijten, Linda W G, additional, Benedetti, Luana, additional, Kuwabara, Satoshi, additional, Van den Bergh, Peter, additional, Monges, Soledad, additional, Marfia, Girolama A, additional, Shahrizaila, Nortina, additional, Galassi, Giuliana, additional, Pereon, Yann, additional, Bürmann, Jan, additional, Kuitwaard, Krista, additional, Kleyweg, Ruud P, additional, Marchesoni, Cintia, additional, Sedano Tous, María J, additional, Querol, Luis, additional, Martín-Aguilar, Lorena, additional, Wang, Yuzhong, additional, Nobile-Orazio, Eduardo, additional, Rinaldi, Simon, additional, Schenone, Angelo, additional, Pardo, Julio, additional, Vermeij, Frederique H, additional, Waheed, Waqar, additional, Lehmann, Helmar C, additional, Granit, Volkan, additional, Stein, Beth, additional, Cavaletti, Guido, additional, Gutiérrez-Gutiérrez, Gerardo, additional, Barroso, Fabio A, additional, Visser, Leo H, additional, Katzberg, Hans D, additional, Dardiotis, Efthimios, additional, Attarian, Shahram, additional, van der Kooi, Anneke J, additional, Eftimov, Filip, additional, Wirtz, Paul W, additional, PA Samijn, Johnny, additional, Gilhuis, H Jacobus, additional, DM Hadden, Robert, additional, Holt, James KL, additional, Sheikh, Kazim A, additional, Kolb, Noah, additional, Karafiath, Summer, additional, Vytopil, Michal, additional, Antonini, Giovanni, additional, Feasby, Thomas E, additional, Faber, Catharina, additional, Kramers, Hans, additional, Busby, Mark, additional, Roberts, Rhys C, additional, Silvestri, Nicholas J, additional, Fazio, Raffaella, additional, van Dijk, Gert W, additional, Garssen, Marcel PJ, additional, Verschuuren, Jan, additional, Harbo, Thomas, additional, and Jacobs, Bart C, additional

Published
2023
Full Text
View/download PDF

41. Supplementary Figure 1 from Effector Regulatory T Cells Reflect the Equilibrium between Antitumor Immunity and Autoimmunity in Adult T-cell Leukemia

Author

Ureshino, Hiroshi, primary, Shindo, Takero, primary, Nishikawa, Hiroyoshi, primary, Watanabe, Nobukazu, primary, Watanabe, Eri, primary, Satoh, Natsuko, primary, Kitaura, Kazutaka, primary, Kitamura, Hiroaki, primary, Doi, Kazuko, primary, Nagase, Kotaro, primary, Kimura, Hiromi, primary, Samukawa, Makoto, primary, Kusunoki, Susumu, primary, Miyahara, Masaharu, primary, Shin-I, Tadasu, primary, Suzuki, Ryuji, primary, Sakaguchi, Shimon, primary, and Kimura, Shinya, primary

Published
2023
Full Text
View/download PDF

42. Supplementary Table 1 from Effector Regulatory T Cells Reflect the Equilibrium between Antitumor Immunity and Autoimmunity in Adult T-cell Leukemia

Author

Ureshino, Hiroshi, primary, Shindo, Takero, primary, Nishikawa, Hiroyoshi, primary, Watanabe, Nobukazu, primary, Watanabe, Eri, primary, Satoh, Natsuko, primary, Kitaura, Kazutaka, primary, Kitamura, Hiroaki, primary, Doi, Kazuko, primary, Nagase, Kotaro, primary, Kimura, Hiromi, primary, Samukawa, Makoto, primary, Kusunoki, Susumu, primary, Miyahara, Masaharu, primary, Shin-I, Tadasu, primary, Suzuki, Ryuji, primary, Sakaguchi, Shimon, primary, and Kimura, Shinya, primary

Published
2023
Full Text
View/download PDF

43. Data from Effector Regulatory T Cells Reflect the Equilibrium between Antitumor Immunity and Autoimmunity in Adult T-cell Leukemia

Author

Ureshino, Hiroshi, primary, Shindo, Takero, primary, Nishikawa, Hiroyoshi, primary, Watanabe, Nobukazu, primary, Watanabe, Eri, primary, Satoh, Natsuko, primary, Kitaura, Kazutaka, primary, Kitamura, Hiroaki, primary, Doi, Kazuko, primary, Nagase, Kotaro, primary, Kimura, Hiromi, primary, Samukawa, Makoto, primary, Kusunoki, Susumu, primary, Miyahara, Masaharu, primary, Shin-I, Tadasu, primary, Suzuki, Ryuji, primary, Sakaguchi, Shimon, primary, and Kimura, Shinya, primary

Published
2023
Full Text
View/download PDF

44. Supplementary Figure 2 from Effector Regulatory T Cells Reflect the Equilibrium between Antitumor Immunity and Autoimmunity in Adult T-cell Leukemia

Author

Ureshino, Hiroshi, primary, Shindo, Takero, primary, Nishikawa, Hiroyoshi, primary, Watanabe, Nobukazu, primary, Watanabe, Eri, primary, Satoh, Natsuko, primary, Kitaura, Kazutaka, primary, Kitamura, Hiroaki, primary, Doi, Kazuko, primary, Nagase, Kotaro, primary, Kimura, Hiromi, primary, Samukawa, Makoto, primary, Kusunoki, Susumu, primary, Miyahara, Masaharu, primary, Shin-I, Tadasu, primary, Suzuki, Ryuji, primary, Sakaguchi, Shimon, primary, and Kimura, Shinya, primary

Published
2023
Full Text
View/download PDF

45. Supplementary Table 2 from Effector Regulatory T Cells Reflect the Equilibrium between Antitumor Immunity and Autoimmunity in Adult T-cell Leukemia

Author

Ureshino, Hiroshi, primary, Shindo, Takero, primary, Nishikawa, Hiroyoshi, primary, Watanabe, Nobukazu, primary, Watanabe, Eri, primary, Satoh, Natsuko, primary, Kitaura, Kazutaka, primary, Kitamura, Hiroaki, primary, Doi, Kazuko, primary, Nagase, Kotaro, primary, Kimura, Hiromi, primary, Samukawa, Makoto, primary, Kusunoki, Susumu, primary, Miyahara, Masaharu, primary, Shin-I, Tadasu, primary, Suzuki, Ryuji, primary, Sakaguchi, Shimon, primary, and Kimura, Shinya, primary

Published
2023
Full Text
View/download PDF

49. Current treatment practice of Guillain-Barré syndrome

Author

Verboon, Christine, Doets, Alex Y., Galassi, Giuliana, Davidson, Amy, Waheed, Waqar, Péréon, Yann, Shahrizaila, Nortina, Kusunoki, Susumu, Lehmann, Helmar C., Harbo, Thomas, Monges, Soledad, Van den Bergh, Peter, Willison, Hugh J., Cornblath, David R., and Jacobs, Bart C.

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results